In September 2019, Anglia Ruskin University’s (ARU’s) Cambridge campus will begin the first year of its new – and currently unique in the UK – Data Scientist Degree Apprenticeship for the bioinformatics profession. Ahead of this, ARU and the Wellcome Sanger Institute have set up a “Lunch and Learn” panel event for hiring managers and talent acquisition specialists, looking at how they can best recruit and support top apprentices.
A neuron-optimised CRISPR-Cas9 activation system has been used by scientists to regulate genes in a rat brain for the first time. This technique could lead to researchers being able to probe genetic influences on brain health and disease in model organisms which more closely resemble humans.
New information from China has suggested that the twins recently created using CRISPR gene-editing technology to make them HIV-resistance could also develop genetically-enhanced brains.
Researchers from the Wake Forest Institute for Regenerative Medicine (WFIRM) have determined a new way to deliver DNA editing tools so that the presence of their proteins in cells is reduced, in what they have called a “hit and run” approach.
Scientists have used synthetic nucleotides to double the traditional number of life’s building blocks to eight.
A combination of immunotherapy drug avelumab and targeted agent axitinib has been seen to increases progression-free survival in patients with metastatic kidney cancer, scientists from the Dana-Farber Institute have reported following a phase 3 clinical trial.
Global life science researcher Bio-Rad has announced that its droplet digital PCR-based test for chronic myeloid leukaemia (CML), the first of its kind, has been cleared by the FDA. The test quantifies BCR-ABL, the gene fusion which causes CML, in the blood.
TEXLab, a mathematical AI software created by scientists at Imperial College London and the University of Melbourne can predict survival rates of patients with ovarian cancer more accurately than any current method, a trial published in Nature Communications has found.
The leading advisor for the UK science and technology (S&T) sectors has estimated that despite Brexit, Cambridge and Oxford’s S&T companies will require 2.5 million more square feet of lab and research space over the next five years, and are looking to accommodate 20,000 new R&D workers by 2023.
Esketamine, a Johnson & Johnson antidepressant based on the party drug ketamine, has received backing from an FDA independent advisory group.
Toxic antibody tisutumab vedotin (TV) has shown promise as a treatment for a number of types of advanced cancer. This “trojan horse” approach has now reached the stage of being tested on a wider variety of patients. Institute of Cancer Research and Royal Marsden NHS Foundation Trust researchers tested the drug on 147 patients to evaluate potential benefits and side effects.
More errors occur in DNA replication during times of stress when resources are scares, scientists at the University of Toronto have found.
For the first time, scientists have changed human stem cells into functional insulin-producing cells in mice, potentially promising a breakthrough in treatment for those suffering from type 1 diabetes.
Oxford Nanopore has launched its two new “109” cDNA kits, which provide high throughput while generating complete sequences of full-length cDNA strands with a low input option of just 1ng PolyA+ RNA.